trial

Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

NCTId NCT00125138
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 90 (actual)
Sponsored by Lundbeck Canada Inc.
Primary completion 2008-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
90 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-07
Primary completion
2008-03
Eligibility
ALL

Interventions & indications

Drugs
Melperone HCl

Sponsors

Lundbeck Canada Inc.Lead Sponsor

Sites

21 total
Tucson, United StatesBradenton, United StatesTampa, United StatesKansas City, United StatesBingham Farms, United StatesGolden Valley, United StatesSt Louis, United StatesCharlotte, United StatesCincinnati, United StatesSan Antonio, United StatesVisakhapatnam, IndiaBangalore, India

Linked catalysts

1
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkins — primary completion2008-03

Facts & assertions

4 sourced
Enrollment
90
Phase
PHASE2
Primary Completion Date
2008-03
Status
COMPLETED
relationships
The graph out of here
drug
Melperone HCl
drug
lead_sponsor
Lundbeck Canada Inc.
company
indication
Psychotic Disorders
indication
Parkinson's Disease
indication
Parkinson Disease
indication